Bone metastases radiopharmaceuticals: An overview

Current Radiopharmaceuticals

Volumn 6, Issue 1, 2013, Pages 41-47

  Cuccurullo, Vincenzo ^a   Cascini, Giuseppe Lucio ^b   Tamburrini, Oscar ^b   Rotondo, Antonio ^a   Mansi, Luigi ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Bone metastases; Bone scintigraphy; F 18 fluoride; F 18 Fluoro Deoxyglucose; Onco tropic radio agents; Tc 99m diphosphonates

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 6 FLUORODOPA F 18; BISPHOSPHONIC ACID DERIVATIVE; FLUORINE 18; PASIREOTIDE TETRAXETAN GALLIUM GA 68; PENTETREOTIDE IN 111; PYROPHOSPHATE; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M;

BONE DEVELOPMENT; BONE GROWTH; BONE LESION; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; HEART MUSCLE PERFUSION; KIDNEY CARCINOMA; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; VASCULARIZATION;

3-IODOBENZYLGUANIDINE; BONE NEOPLASMS; CHOLINE; DIHYDROXYPHENYLALANINE; DIPHOSPHONATES; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; SODIUM FLUORIDE; SOMATOSTATIN; TECHNETIUM; THYMIDINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84881599690     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011306010007     Document Type: Review

References (48)

1. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat. Rev. Clin. Oncol., 2011, 9(2), 76-78.
2. Greco C, Forte L, Erba P, Mariani G. Bone metastases, general and clinical issues. Q. J. Nucl. Med. Mol. Imaging, 2011, 55(4), 337-352.
3. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin. Exp. Metastasis, 2007, 24(8), 599-608.
4. Coleman RE. Metastatic bone disease: clinical features, patho-physiology and treatment strategies. Cancer Treat Rev., 2001, 27, 165-176.
5. Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities. Q. J. Nucl. Med. Mol. Imaging, 2011, 55(4), 374-410.
6. Cuccurullo V, Cascini G, Rossi A, Tamburrini O, Rotondo A, Mansi L. Pathophysiological premises to radiotracers for bone me-tastases. Q. J. Nucl. Med. Mol. Imaging, 2011, 55(4), 353-373.
7. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q. J. Nucl. Med., 2001, 45: 53-64.
8. Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third eye. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(10), 1519-1524.
9. Cascini G, Falcone C, Greco C, Bertucci B, Cipullo S, Tamburrini O. Whole-body magnetic resonance imaging for detecting bone metastases: comparison with bone scintigraphy. Radiol. Med., 2008, 113(8), 1157-1570.
10. Berritto D, Somma F, Landi N, Cavaliere C, Corona M, Russo S, Fulciniti F, Cappabianca S, Rotondo A, Grassi R. Seven-Tesla mi-cro-MRI in early detection of acute arterial ischaemia: evolution of findings in an in vivo rat model. Radiol. Med., 2011, 116(6), 829-841.
11. S.L. Kitson, V. Cuccurullo, A. Ciarmiello, D. Salvo, L. Mansi. Clinical Applications of Positron Emission Tomography (PET) Im aging in Medicine: Oncology, Brain Diseases and Cardiology. Cur rent Radiopharmaceuticals, 2009, 2, 224-253.
12. Atkins HL, Srivastava SC. Radiolabeled bone-seeking radiophar-maceuticals. Q. J. Nucl. Med., 1996, 40(3), 285-289.
13. Pauwels EK, Stokkel MP. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice. Q. J. Nucl. Med., 2001 Mar, 45(1), 18-26.
14. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J. Nucl. Med., 1975, 16(8), 744-755.
15. Deutsch E, Libson K, Becker CB, Francis MD, Tofe AJ, Ferguson DL, McCreary LD. Preparation and biological distribution of technetium diphosphonate radiotracers synthesized without stannous ion. J. Nucl. Med., 1980, 21(9), 859-866.
16. Francis MD, Ferguson DL, Tofe AJ, Bevan SA, Michaels SE. Comparative evaluation of three diphosphonates: in vivo adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J. Nucl. Med., 1980, 21, 1185-1189.
17. Charkes ND. Skeletal blood flow: implications for bone scan interpretation. J. Nucl. Med., 1980, 21, 91-98,
18. Potsaid MS, Guiberteau MJ, McKusick KA. Quality of bone scans compared with time between dose and scan. J. Nucl. Med., 1977, 18(8), 787-789.
19. Fogelman I, Pearson DW, Bessent RG, Tofe AJ, Francis MD. A comparison of skeletal uptakes of three diphosphonates by whole-body retention. J. Nucl. Med., 1981, 22(10), 880-883.
20. Krishnamurthy GT, Huebotter RJ, Tubis M, Blahd WH. Pharmaco-kinetics of current skeletal-seeking radiopharmaceuticals. AJR Am. J. Roentgenol., 1976, 126(2), 293-301.
21. Silberstein EB: A radiopharmaceutical and clinical comparison of 99mTc-Sn-hydroxy-methylene diphosphonate with 99mTc-Sn-hydroxyethylidene diphosphonate. Radiology, 1980, 136, 747-751.
22. Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q. J. Nucl. Med., 2001, 45(1), 47-52.
23. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J. Nucl. Med., 2008, 49(1), 68-78.
24. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl. Med., 2001, 31(1), 50-61.
25. Hingorani M, Spitzweg C, Vassaux G, Newbold K, Melcher A, Pandha H, Vile R, Harrington K. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr. Cancer Drug Targets, 2010, 10(2), 242-267.
26. Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q. J. Nucl. Med. Mol. Imaging, 2004, 48(2), 82-95.
27. Ambrosetti MC, Colato C, Dardano A, Monzani F, Ferdeghini M. Radioiodine ablation: when and how. Q. J. Nucl. Med. Mol. Imaging, 2009, 53(5), 473-481.
28. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(4), 351-368
29. Novellino F, Bagnato A, Salsone M, Cascini GL, Nicoletti G, Arabia G, Pugliese P, Morelli M, Paglionico S, Cipullo S, Manna I, De Marco EV, Condino F, Chiriaco C, Morgante L, Zappia M, Quattrone A. Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol. Aging., 2010, 31(11), 1903-1911.
30. Cuccurullo V, Mansi L. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(8), 1262-1265.
31. Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q. J. Nucl. Med. Mol. Imaging, 2009, 53(2), 158-166.
32. Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q. J. Nucl. Med. Mol. Imaging, 2005, 49(3), 225-235.
33. Cascini GL, Cuccurullo V, Mansi L. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(1), 24-36.
34. Cuccurullo V, Cascini GL, Tamburrini O, Mansi L, Rotondo A. Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest. Minerva Endocrinol., 2011, 36(1), 41-52.
35. Rambaldi PF, Cuccurullo V, Cascini GL, Mansi L. Our experience in thymic hyperplasia using 67Ga-citrate, 111In-pentetreotide and 201Tl-chloride. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(8), 1616.
36. Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl. Med., 1997, 27(4), 355-363.
37. Kailasnath P, Sinusas AJ. Technetium-99m-labeled myocardial perfusion agents: Are they better than thallium-201? Cardiol. Rev., 2001, 9(3), 160-172.
38. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin. I: Uptake into isolated adult rat ventricular myocytes and subcellular localization. J. Nucl. Cardiol., 1995, 2(4), 317-326.
39. Mansi L, Rambaldi PF, Cuccurullo V, Pecori B, Quarantelli M, Fallanca F, Del Vecchio E. Diagnostic and prognostic role of 99mTc-Tetrofosmin in breast cancer. Q. J. Nucl. Med., 1997, 41(3), 239-250.
40. Ronga G, Ventroni G, Montesano T, Filesi M, Ciancamerla M, Di Nicola AD, Travascio L, Vestri AR, Signore A. Sensitivity of [99mTc]methoxyisobutylisonitrile scan in patients with metastatic differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging, 2007, 51(4), 364-371.
41. Cascini GL, Cuccurullo V, Tamburrini O, Mansi L, Rotondo A. Nuclear medicine in multiple myeloma -- more than diagnosis. Nucl. Med. Rev. Cent. East Eur., 2010, 13(1), 32-38.
42. Peterson JJ. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. Semin Musculoskelet. Radiol., 2007, 11(3), 246-260.
43. Oyen WJ, Mansi L. FDG-PET in infectious and inflammatory disease. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(11), 1568-1570.
44. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl. Med., 2005, 35(2), 135-142.
45. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(11), 2188-2193.
46. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl. Med., 2007, 37(6), 420-428.
47. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. Semin Nucl. Med., 2007, 37(6), 429-439.
48. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl. Med., 2007, 37(6), 400-419.